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Abstract
Aim
To study population pharmacokinetics and pharmacogenetics of ritonavir boosted atazanavir using exactly recorded drug intake time
by MEMS.
Methods
The ANRS134 COPHAR 3 trial was conducted in 35 HIV-infected treatment-na ve patients. Atazanavir (300 mg), ritonavir (100 mg),– ï
and tenofovir (300 mg)  emtricitabine (200 mg) were supplied in bottles with a MEMS cap to be taken once daily during 6 months.+
Six concentrations measurements were collected at week 4, then trough levels bimonthly. A model integrating atazanavir and
ritonavir pharmacokinetics and pharmacogenetics was developed using non-linear mixed effects.
Results
Use of exact dosing history data halved unexplained variability in atazanavir clearance. Ritonavir-atazanavir interaction model
suggested that optimal boosting effect is achievable by lower ritonavir exposures. Patients with at least one copy of the CYP3A5 1*
allele exhibited 42  increased oral CL.%
Conclusion
We provide evidence that variability in atazanavir pharmacokinetics is defined by adherence, CYP3A5 genotype and ritonavir
exposure.
MESH Keywords Adenine ; analogs & derivatives ; therapeutic use ; Adult ; Aged ; Alleles ; Cytochrome P-450 CYP3A ; genetics ; Deoxycytidine ; analogs & derivatives 
; therapeutic use ; Drug Interactions ; Drug Therapy, Combination ; Female ; Genotype ; HIV Infections ; drug therapy ; HIV Protease Inhibitors ; pharmacokinetics ; 
pharmacology ; therapeutic use ; Humans ; Male ; Medication Adherence ; Middle Aged ; Models, Biological ; Nonlinear Dynamics ; Oligopeptides ; pharmacokinetics ; 
therapeutic use ; Organophosphonates ; therapeutic use ; Pharmacogenetics ; Pyridines ; pharmacokinetics ; therapeutic use ; Ritonavir ; pharmacology ; therapeutic use ; Young
Adult
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INTRODUCTION
Atazanavir (ATV) is a potent HIV-1 protease inhibitor (PI) used as a principal component of combined antiretroviral therapy (cART)
for first line HIV treatment since 2003(1, 2). Its pharmacologic characteristics allow for once daily dosing either as a 300 mg capsule
Clin Pharmacol Ther . Author manuscript
Page /2 15
boosted with ritonavir (100 mg) or 400 mg capsule administered with food. In addition to the convenience of once daily dosing, the
advantage of atazanavir over other available PIs lies in its favorable safety profile with respect to the dyslipidemia risk (3).
Despite its favorable pharmacologic properties allowing for once daily dosing, atazanavir pharmacokinetics is associated with high
variability between- and within-patients, posing a challenge for assessing and predicting not only individual exposures but also the target
concentration time profile needed for optimal pharmacotherapeutic management (4 6). Potential sources of large between- and within-– –
patient variability can be multiple: a) the food effects on oral bioavailability and absorption, b) drug-drug interactions, c) variability in
ritonavir boosting, d) a large array of plausible pharmacogenetics interactions e) adherence variability. Additionally, high atazanavir
concentrations have been associated with important toxicities, for example hyperbilirubinaemia. In patients with HIV virus sensitive to
atazanavir, the current targets for the therapeutically optimal range of trough concentrations are at a lower boundary of 150 ng/mL, the
minimum effective concentration (MEC) for successful viral suppression as reported in the US Department of Health and Human Services
guidelines for antiretroviral therapy, and an upper boundary of 850 ng/mL, defined as a concentration threshold for bilirubinemia (4, 7).
The human cytochromes P450 3A4/3A5 (CYP3A5) are implicated in the hepatic metabolism of atazanavir (8, 9). CYP3A5 is mainly
expressed in the liver and has a strong genetic basis (10). Low expression of CYP3A5 is found in homozygous carriers of the CYP3A5*3
allele, whereas homozygous and heterozygous carriers of the  allele exhibit high expression of CYP3A5 (10). The decreased (26CYP3A5*1
) atazanavir CL in CYP3A5 non-expressors has been recently reported in a study with healthy volunteers (11). In addition, there are%
known polymorphisms associated with UGT1A1, and functional deficiencies result in the accumulation of unconjugated bilirubin in the
serum although there is variability in the phenotypic expression of patients carrying genetic polymorphism. Rotger , showed thatet al
individuals with the  allele may develop jaundice when exposed to atazanavir or indinavir (12).UGT1A1 28*
Variable adherence to the prescribed therapy adds an additional general level of complexity in maintaining optimal ARV drug
treatment. This topic has been in wide discussion in the last decade (13, 14). Both, poor outcome of treatment and selection of resistant
viral strains, have been linked to suboptimal adherence (15 20). Additionally, variable adherence is most likely one of the major–
contributors to the observed pharmacokinetic variability within and even between patients especially for long term treatments (21 24).–
Different methods have been proposed for measuring adherence. However in order to assess and quantify the impact of adherence on
dynamic systems, such as time courses of the viral load, bilirubin concentrations or PI pharmacokinetics, the adherence pattern needs to be
known as well. A precise assessment of adherence may be performed with Medication Event Monitoring System (MEMS)(21, 25, 26),
which records exact times of bottle opening for drug intake in combination with informative study design that allows for precise
quantification of individual drug exposure and variability.
Undoubtedly, the interplay between individual pharmacokinetics, pharmacogenetics and adherence is complex and of critical
importance to maintain atazanavir concentrations within the optimal therapeutic range, which would in turn minimize the incidence of
therapeutic failure, development of drug-resistance and development of other toxicities Several previous studies developed population
pharmacokinetic models for atazanavir (4 6). These studies reported high unexplained between subject variability in atazanavir PK–
parameters and suggested that adherence, pharmacogenetics and variability in ritonavir exposure are likely responsible for that but none of
these studies had adherence measured via MEMS. Therefore, our study focused on elucidating these relationships in a data-driven
quantitative manner. Our aims were: (i) to describe the population PK of atazanavir using accurate patient dosing-histories, (ii) to
investigate how different assumptions involved in maximizing the accuracy of dosing-history data may impact the population PK analysis
outcomes, (iii) to quantify pharmacogenetic effects of different relevant single nucleotide polymorphism (SNPs) on atazanavir
pharmacokinetics, (iv) to establish a joint ritonavir atazanavir pharmacokinetic model to include the boosting mechanism and (v) to—
estimate realistically variables linked to effectiveness of cART(24, 27), using the established model, such as cumulative time and the
number of trough samples below MEC during 24 weeks of trial.
RESULTS
Patients and data
The 35 patients included were 6 females and 29 males with a median age of 36 years (range 24 66).Median viral load (VL) and CD4–
count at inclusion were 23,200 copies/mL (range, 100 457,000) and 436 cells/mm (range, 197 573) respectively. Clinical and safety– 3 –
results of the trial were presented elsewhere (28). In brief, only 5 of the 35 patients did not achieve undetectable VL(<40 cp/mL) at W24,
with a range of 47 to 152 cp/ml, one patient experienced a severe hyperbilirubinemia (grade 4) with a high atazanavir trough concentration
and discontinued ritonavir and one patient experienced a transient cytolytic hepatitis (grade 4) of unknown origin.
In total, 272 atazanavir and 245 ritonavir concentrations from the 35 patients followed during a six-month period were available for
the analysis. Raw atazanavir data are shown in Figure 1, where a full profile can be observed as well as trough values at different
occasions. Inspection of the raw data indicated high variability in the absorption phase as well as substantial within-subject variability in
the trough samples. Median observed maximal (C ) and trough concentrations (C ) of atazanavir at W4 were 4,021 ng/mL (range,max trough 
1,903 2,907), and 304 ng/mL (range, 40 2,366), respectively.– –
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Adherence data
Statistical analysis of raw adherence data indicated almost perfect adherence to medications in the studied population with a majority
of the prescribed doses were taken as prescribed: median 100  (range 50 100) and median 99.7  (range 51 100)for atazanavir and% – % –
ritonavir, respectively. The percentage of doses taken on time ( 3 hours) was somewhat lower: median 88.2  (range 31.7 100) and± % –
median 86.6  (range 30.4 100) for atazanavir and ritonavir, respectively. The deviations from MEMS recorded intake was reported only% –
twice. Similar adherence behavior was observed for tenofovir and emtricitabinepill. The dose-intensity heat maps showing adherence
dynamics (incidence and amount of dose intake versus time for each patient) are shown in Figure 2.
Population PK model for atazanavir
A one-compartment model described atazanavir disposition well. The transit compartment absorption model substantially improved
the observed data fit compared to all investigated absorption models. When compared to the second best absorption model (first order with
a lag time), the transit model decreased 2 log likelihood by 64 points (p<10 ), and also explained an additional 11  of residual− 14 − %
variability at the cost of two additional parameters. The comparison of model fits with both the transit and the first order absorption model
with a lag time are shown in Figure 3. The proposed transit compartment model was parameterized in terms of the following parameters:
number of transit compartments (NN), mean transit time (MTT) which is the average time for a molecule to reach the absorption site, and
absorption rate constant (ka).
Impact of adherence assumptions on the outcome of the population PK analysis
With respect to population PK data analysis, the assumption that all patients are at SS gave rise to significant quantifiable
inter-occasion variability in CL/F (26.5  CV). The second analysis (A ) in which patient actual MEMS dosing-history were used, led% MEMS 
to a negligible within-subject variability estimate indicating that MEMS data explained this variability term entirely. However, a biased
estimate of the volume of distribution was observed, thereby potentially affecting the prediction of individual patient s drug exposures.’
Numerical difficulties during the estimation procedure were also experienced. In the gold standard analysis, a small proportion of the
records of time of dose intake (<5 ) were found to be discordant compared to the self-reported dose intake time, therefore excluded from%
the analysis. That gold standard analysis (A ) based on adjusted dosing histories only, led to the negligible within-subject variability inGOLD 
CL; parameter estimates were reliable, and the estimation procedure was stable. The parameter estimates from the three different analyses
are shown in the Table I.
Pharmacogenetics and covariates
Pharmacogenetic data analysis revealed a statistically significant (p<0.01) effect of the CYP3A5 polymorphism on the atazanavir CL.
Patients with at least one copy of the  allele (n 12) exhibited 42  increased oral CL compared with patients with both CYP3A5 1* = % CYP3A5*
 allele. None of other demographic and genetic covariates deemed to be important. The visual predictive check for the final model3
stratified for different CYP3A5 genotypes is shown in Figure 4.
Joint ritonavir-atazanavir model
Ritonavir concentration time profiles were best described with the one compartment model. Absorption was described well with the
transit compartment absorption model. Parameter estimates of the final ritonavir PK model are given in the Table 2. Ritonavir exposure
(AUC ) defined as dose divided by individual CL was a sufficient driver to explain the boosting mechanism of atazanavir CL. The0-24 
estimate of unboosted atazanavir CL, e.g. in the absence of ritonavir, was rather high (16 L/h). Ritonavir proved to be an efficient booster
exhibiting maximal inhibitory effect of 98  with AUC of 6,230 ng.h/mL, which was on the lower end of the observed ritonavir exposure% 50 
in this study (7 percentile). The schematic view of the proposed model is shown in Figure 5. The increase in atazanavir CL for the carriersth 
of the  allele was 28  after inclusion of ritonavir-boosting mechanism. The parameter estimates for the final PKPG model areCYP3A5 1* %
given in the Table II.
Model Predictions and Simulations
The number of trough samples and the cumulative time below MEC over 24 weeks were computed for each patient (180 trough values
for each patient). If the adherence was perfect, none of the trough samples would be below MEC (150 ng/mL), except for one individual
who had an extremely high CL and was a  carrier, and whose trough values were all below the target level. And thereforeCYP3A5 1*
similar result holds for the cumulative time below this threshold. However, when the true MEMS dosing histories were used, during the 24
weeks, 4patients (12 ) had more than 10 trough samples below the MEC of 150 ng/mL and 8 patients (24 ) spent more than 100 h% %
below MEC.
DISCUSSION
Clin Pharmacol Ther . Author manuscript
Page /4 15
Today, there are more HIV patients on the planet who do not have the access to powerful protease inhibitors than the ones who do
have the access to PIs. For those HIV patients who do have the access to effective PI-based HIV treatment, successful management of the
HIV therapy still presents a great challenge both for the physician and the patient. Complex interplay between highly variable drug specific
pharmacokinetics, patient adherence, and genetic background of the patient poses difficulties in maintaining the optimal therapeutic levels
of the PIs required in order on one hand, to minimize the risk of therapeutic failure associated with the risk of viral resistance, and on the
other hand, to prevent drug-related toxicities. A fully integrated pharmacokinetic-pharmacogenetic model with an integrated
ritonavir-related boosting mechanism and real time adherence data was developed for atazanavir pharmacokinetics.
In this study, atazanavir disposition was best described by a one compartment model, which is in line with previous modeling studies
(4 6). Kile  found that two compartment model was best fit for atazanavir pharmacokinetics, which was not the case for our data. This– et al
is likely due to the design: Kile  collected very rich data in healthy volunteers (9 samples) while we collected6 samples in patients. Itet al
is common that with very rich design, more complex models can be applied. However, we do not anticipate that this would alter any of our
major findings.
In the absence of ritonavir-related boosting and pharmacogenetic relationships, apparent atazanavir CL and V were 6.9 L/h and 81.1 L,
respectively, resulting in an elimination half-life of 8.1 h, which is consistent with previously reported values (8.2 8.9 h) (4 6). Our work– –
departs from previously published atazanavir models in reporting our evaluation of relevant absorption models. Our study implemented a
semi-mechanistic transit compartment model in order to describe highly variable atazanavir absorption. The transit model assumes that the
delay in the absorption process is a consequence of the drug passing through chain of linked compartments (steps), before reaching the
absorption site (29). Our analysis illustrates that the transit compartment model is an attractive alternative for the modeling of the variable
absorption, especially for anti-infective agents (30, 31).
Ritonavir has been developed and used as a pharmacokinetic booster of protease inhibitors (32). Ritonavir is a potent inhibitor of
CYP3A4, the primary enzyme responsible for the metabolism of PIs, therefore decreasing the clearance and increasing half life of PIs and
providing a basis for increasing the dosing interval to once daily (QD). The most common dose used for boosting is a 100 mg capsule per
PI dosing. In our integrated model, the ritonavir-related boosting mechanism of atazanavir CL/F has been introduced. It was best described
by the inhibitory E model, where the baseline atazanavir CL value in the absence of ritonavir was estimated (16 L/h, which is similar tomax 
previous reports(11)) as well as maximal extent of inhibition and ritonavir exposure needed for half maximal effect. Ritonavir is an
established and proven potent booster with maximal (98 ) inhibition of atazanavir CL, suggesting that a majority of the patients have been%
maximally boosted. Interestingly, a lower value of ritonavir exposure (6,230 ng.hr/mL) is estimated to be needed for half maximal
ritonavir boosting effect. This estimated ritonavir exposure is at the lower end of the observed ritonavir exposures (7 percentile), whichth 
suggest potential overdosing of ritonavir in most patients, whereby lower doses of ritonavir could produce the desired boosting effect in
order to maintain once daily atazanavir dosing. This result may be of interest considering the fact that 100 mg qd ritonavir has been
implicated in increased risk of lipid level increase (33, 34). Furthermore, ritonavir may also be responsible for gastrointestinal adverse
events experienced during treatment with PIs, therefore potentially affecting the adherence to PIs and ultimately the success of HIV
therapy (35).
Atazanavir is primarily metabolized by CYP3A4/A5 and pharmacogenetic differences are expected to be observed with respect to the
bioavailability and clearance of the drug. Even though our study was rather small (35 patients), we have quantified a significant increase in
atazanavir CL (28 ) in the patients with at least one  allele, which is similar to the previously reported values (9). Kile % CYP3A5 1* et al
reported 26  difference in unboosted atazanavir CL/F in healthy volunteers with different CYP3A5 genotypes. Our study confirms their%
findings in na ve HIV patients but also provides evidence that this effect is significant in presence of ritonavir and is of same magnitude atï
steady state.
Adherence to the prescribed therapy has been repeatedly named as the key factor for successful treatment outcome. Importantly,
adherence will contribute to the observed pharmacokinetic variability. This fact is critical when drug levels must be maintained within a
desired therapeutic window, or specifically in the case of PIs, above minimal effective concentrations. Furthermore, the ultimate goal of all
model-based analysis is not only to quantify random variability between subjects, but also to explain these differences by plausible
covariates. Ultimately, if almost of the variability in drug response can be explained, it would provide a basis for personalized dosing
regimens. However, even-though a large number of demographic and pharmacogenetic covariates are often available for the analysis, only
a small portion of the observed variability is explained. We hypothesized that adherence fluctuations would explain the majority of the
observed variability. Therefore, we performed a sub-analysis of our data focusing on assumptions surrounding dosing histories. Our first
analysis, which is in line with an implicit assumption in most population PK analyses, assumed perfect adherence and that all patients were
at steady state. Under the steady-state assumption, the random variability in CL/F was 74 , corresponding to 47  of between-subject% %
variability and 27  within-subject (or between-occasion) variability. Once MEMS adherence data from only reliable-patients  were% “ ”
included, the between-subject variability in CL/F decreased to 40 , while the within-subject variability became negligible. This finding%
suggests that almost half of the initially quantified variability was not true variability in clearance, but was attributable to the unwarranted
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assumption of perfect adherence by all patients. This finding also reminds one that important covariates (e.g., weight, age,
pharmacogenetics, etc), do not explain such a large portion of variability. It is consistent however, with the conclusion of Harter and Peck
that variability in adherence rivals pharmacokinetics as the leading source of variability in drug response (36).
In our study, we have measured adherence using the MEMS caps, which record the exact time of the bottle opening. In most of the
cases, the opening of the drug bottle corresponds to the drug intake; however some deviations to this assumption may occur. To obtain
data closest to the truth, we asked subjects to keep a diary where these deviations were recorded. In addition, at each clinic visit, we asked
them to report the time of drug intake from the previous day. This information was very helpful since we could compare the MEMS
records with the individual s diary entry, and most of them agreed. A small proportion of the records (<5 ) were discordant, leading to’ %
identifying these patient records as unreliable . Even though the proportion of unreliable data points was small, it was important to“ ”
exclude them from the analysis, in order to generate a gold standard cohort for comparison, increase model stability and guarantee analysis
convergence.
In general, patient adherence in our study was very good. 98  of all atazanavir and ritonavir doses and 86  of the pills were taken by% %
patients as prescribed. However, despite this high adherence rate, we showed that a few patients had atazanavir plasma levels below the
target minimal effective concentration during the course of the treatment. Even though the median value of the time below MEC was low
(<1  of the dosing interval), some of the patients spent up to 15  of the dosing interval below MEC. More precisely, there were five% %
patients who were, over the treatment course, more than a cumulative 7days with unacceptably low levels of atazanavir. Two of these
patients were non-responders at week 24 (out of the 5 non responders). The example of one of these patients is shown in Figure 6 where a
full PK profile over 6 months is shown as well as the accumulated time below MEC. If the dosing regimen intake was perfect, none of the
patients would be below MEC at any time during treatment. This suggests that even though overall adherence may be high, patients still
fall below MEC, and are therefore at risk of treatment failure, if the drug intake is not-timely. This finding accentuates the importance of
estimating adherence not only as an aggregate measure over a defined period of time, but also the precise time of each capsule intake. Only
when we have this data in hand are we able to search and find plausible answers why treatment may have failed or resistance developed.
Two main limitations of the current study are small sample size (35 patients) and the protocol may have induced better adherence
(Hawthorne effect).
In conclusion, a full, integrated pharmacokinetic-pharmacogenetic model for atazanavir with incorporated ritonavir-related boosting
mechanism and real time adherence was developed for atazanavir pharmacokinetics. With the proposed model, we have delineated and
quantified several important aspects of atazanavir-based HIV treatment. We have i) quantified a significant pharmacogenetic effect of
CYP3A5 genotype on atazanavir CL, ii) characterized the pronounced ritonavir-related boosting mechanism of atazanavir CL at currently
used ritonavir doses, and iii) assessed the large effect of adherence on atazanavir PK variability. The proposed model represents a useful
basis for the individualized dosing of atazanavir and provides a precise tool for assessing the important PK-based variables (e.g. time
below MEC) for successful HIV-treatment.
METHODS
Clinical trial
The ANRS 134 - COPHAR 3 trial was a multicenter prospective trial conducted in HIV-1-infected na ve patients starting aï
PI-containing cART treatment. The primary objective of the trial was to study pharmacokinetics/pharmacogenetics of atazanavir given
with ritonavir using adherence measured by MEMS in PI treatment-na ve HIV-infected patient.ï
The trial started and was completed in 2008. It included 35 na ve patients, who were started on treatment containing 300 mg ofï
atazanavir boosted with 100 mg ritonavir and a fixed dose combination of two nucleoside analogs that are co-formulated: tenofovir (300
mg) and emtricitabine (200 mg) and were followed 24 weeks. Reyataz (atazanavir) and Truvada (tenofovir and emtricitabine) were ®  ®
kindly provided by Bristol-Myers Squibb and Gilead, respectively. Viruses have to be sensitive to each component of therapy on a
genotypic resistance assay performed before entry. No antacids or CYP inducing drugs were allowed during the trial. During the PK visit,
drug intake was performed with food administration.
The study was performed according to the Declaration of Helsinki and its amendments. The protocol was approved by the Ethics
Committee of Ile de France VII (Le Kremlin Bicetre, France) and all subjects provided written informed consent. The EUDRA CT number
is 2007-003203-12.
Study design and Pharmacokinetic data
Patients were sampled during four visits at weeks (W) 4, 8, 16 and 24. During each visit, the patients were asked to report the exact
time when the last dose was taken in the previous day. At W4, a trough blood sample was collected first, followed by the dose intake and
collection of additional five samples at 1, 2, 3, 4, and 8 hours post-dose. At W8, W16 and W24, only the trough samples were collected.
Therefore, each individual had 9 PK samples available over a period of 6 months. Plasma concentrations were determined in the
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laboratories of the hospitals where the patients were followed by a specific high performance liquid chromatography (HPLC) protocol. The
participant laboratories were cross-validated before starting the study. The lower limit of quantification was 50 ng/mL and 25 ng/mL for
atazanavir and ritonavir, respectively.
Adherence data
Each patient was supplied with three MEMS capped bottles containing either atazanavir hard-capsules, ritonavir soft-capsules or
tenofovir/emitricabine FDC tablets (Truvada ). The exact time of each opening of the cap was recorded. Therefore a full dosing history®
for the three capsules was available for all the patients. Patients were also requested to note any deviations from MEMS recorded drug
intake, for example if a patient would leave for a short holiday and remove the requisite supply of pills in a single cap opening.
Additionally, at each clinic visit, patients were asked to report on a self administered questionnaire the time of the previous dose intake,
which allowed for comparison with the MEMS recorded time.
Each patient whose MEMS record agreed with his or hers personal declared record within 3 hours was considered to have a reliable±
MEMS dosing history, indicating that the MEMS recorded time was similar to the time of actual drug intake. If a MEMS record did not
agree with patient s personal record, this record was considered less reliable and the dosing history preceding the clinical visit was’
discarded from the analysis as well as collected sample at the clinical visit, when gold standard approach analysis was used (more details
below).
Pharmacogenetic data
Six genetic polymorphisms were studied: MRP2 (rs717620), MRP4 (rs1751034), ORM1 (A721G), CYP3A5 (rs776746), MDR1
(rs1045642) and UGT1A1 28 (rs8175347).All of the genotyping analyses were performed in the same laboratory. The subjects were*
genotyped by the TaqMan allelic discrimination assay or GeneScan analysis. For both methods, genomic DNA was extracted from
peripheral blood mononuclaear cells using the Puregene Kit (Gentra systems, Minneapolis, USA) according to the manufacturer s protocol.’
For each polymorphism, departure from Hardy-Weinberg proportions was tested using test with degrees of freedom equal to the numberχ2 
of observed genotypes minus 1.
Data analysis
Development of population model for atazanavir
All data were analyzed using the non-linear mixed effects approach available in NONMEM VI. The First Order Conditional
Estimation with interaction (FOCEI) method was employed throughout the analysis. A basic model structure was established using the full
PK profile data from W4 and assuming steady state conditions. As atazanavir exhibit highly variable absorption, special attention was paid
to the modeling of this process. Several models were investigated, including the zero order absorption models, first order absorption model
with lag time, sequential zero and first order model, transit absorption model. The individual parameters were assumed to be log-normally
distributed and proportional error was employed for description of residual variability. The model building procedure was guided by the
likelihood ratio test, diagnostic plots and internal model validation techniques, including visual and numerical predictive checks.
Adherence modeling
Adherence data were summarized in terms of following statistical quantities: percent ( ) of days with correct number of doses taken, %
 of total prescribed doses taken and  of doses taken within  3 hours of the protocol specified dosing time. Adherence data were also% % ±
explored using a graph where daily adherence behaviors, such as if dose was taken, taken twice or missed, were visualized for each patient
and each drug. This plot is often referred to as a dose intensity gap map . In order to assess the impact of dosing history assumptions on“ ”
the outcome of the population analysis, we performed three separate analyses from the entire atazanavir dataset (full PK profile from W4
and three additional trough samples at W8, W16 and W24). The first analysis, based on the assumption of full adherence to the protocol
specified dosing history (A ), included the assumption that all patients were at steady state and that the time of last dose intake as reportedss 
by the patient before a PK visit was accurate. The second analysis, a MEMS recorded dosing history analysis (A ),assumed that eachMEMS 
dosing time recorded by MEMS was accurate. The third analysis, which we termed the gold standard analysis (A ),used reliableGOLD ” ”
dosing-history data only, which consisted only in concentration data from which MEMS records of time of intake were concordant (within
3 hours) with patients last reported time of dose intake before a PK visit. When MEMS data were missing (no MEMS for some patients
sometimes), the corresponding concentration data were not analyzed The previously established basic structural model was extended to
include within-subject variability (WSW) in CL and was rerun using three different dosing history data as described above (A A andss, MEMS 
A ). Parameter estimates were compared with particular attention to the magnitude of the variability parameters (between-subject,GOLD 
within-subject and residual variability).
Pharmacogenetic and demographic covariate analysis
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Six genetic polymorphisms (MRP2, MRP4, MDR1, CYP3A5, UGT1A1,ORM1) were evaluated as possible genetic covariates
influencing pharmacokinetic parameters of atazanavir. Potential impact of these genetic markers on atazanavir and ritonavir
pharmacokinetics are described in Table 1 of supplementary material. Mutant and heterozygotic alleles were grouped together into one
category in order to increase the power of the search. Categorizations in three classes were also tested: wild homozygotes versus
heterozygotes versus mutant homozygotes.
Demographic covariates were also available: age, sex and body weight. The covariate search was performed using a stepwise covariate
model building procedure described elsewhere (37, 38). The procedure included a forward inclusion step, where parameter-covariate
relationships are added to the model in a stepwise manner until no further relationship is statistically significant (p<0.05). Backwards
elimination steps followed, where the identified relationships were excluded from the model if they failed to achieve stricter statistical
significance (p<0.01), in order to account for the multiple testing.
Development of the population models for ritonavir and the joint ritonavir-atazanavir model
Full dosing history data were available for ritonavir and the gold standard approach was used. Ritonavir concentration time data were
modeled using a similar methodology to the one described above for atazanavir.
Once separate ritonavir and atazanavir models were established, the next step involved development of the joint ritonavir-atazanavir
model, where the boosting mechanism was introduced. A range of models was evaluated in which atazanavir CL/F was either: (i) a
function of ritonavir concentrations, (ii) a delayed response to ritonavir concentrations, or (iii) a function of ritonavir steady state exposure.
For the models employing ritonavir concentrations as a driver of the boosting mechanism, both simultaneous and sequential approaches
were tested. Steady state ritonavir exposure was computed as ritonavir dose divided by individual CL value. A model for the boosting
mechanism utilized a nonlinear inhibitory E function, where the maximal boosting effect was estimated as well as AUC , which is themax 50 
ritonavir exposure needed for half maximal effect (Equation 1). CL represents unboosted atazanavir CL.0 
Model simulations and predictions
The final PK-PG model for atazanavir using the dosing history data from the gold standard approach  and the model-estimated“ ”
individual parameters were used to predict different variables linked to effectiveness cART (24, 27). For each patient we estimated, over
the 24 weeks of the trial, (i) the number of trough samples below MEC (150 ng/mL) for wild-type viruses (4, 7), and (ii) the cumulative
time with concentration below MEC. This information were estimated using first a hypothetical perfect dosing regimen, as if drug was
taken every 24h and second using the actual dosing regimen as recorded by MEMS.
CPT Highlights
What is the current knowledge on the topic?
Population pharmacokinetics of CYP3A substrates ritonavir and atazanavir is well understood. Adherence to medication is a key factor
in large concentration variability leading to poor treatment outcome.
What question this study addressed?
The study quantifies the relationship between adherence, CYP3A5 genotype, ritonavir and atazanavir pharmacokinetics in
HIV-infected treatment-na ve patients.ï
What this study adds to our knowledge?
Adherence is the major contributor to variability in atazanavir pharmacokinetics. Oral clearance is increased by 28  in patients with a%
copy of in ritonavir presence. Optimal boosting effect is achievable by lower ritonavir exposures.CYP3A5 1,*
How this might change clinical pharmacology and therapeutics?
The atazanavir therapeutic dose can be individualized based on CYP3A5 genotype. If good adherence is achieved, ritonavir dose can
be lowered. Real time adherence allows calculation of cumulative drug exposure during a treatment period. TDM using a single plasma
sample can be misleading.
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Figure 1
Observed atazanavir concentration, full profile at week 4 (top) and troughs at various occasions (bottom)
Clin Pharmacol Ther . Author manuscript
Page /11 15
Figure 2
Adherence patterns in the study population for atazanavir (top) and ritonavir (bottom). Green fields indicate correct dose intake, red bars
represent days with missed doses, black bars indicate overdosing and blue fields are missing data because of absence of MEMS (patients
CASL had atazanavir MEMS data for 4 weeks only). Each patient is shown as a horizontal bar.
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Figure 3
Comparison of individual model fits with the transit compartment model and first order absorption model with a lag time for three patients.
The best, average and worst fits were chosen based on the median value of absolute individual weighted residuals.
Figure 4
Visual predictive check for the final atazanavir model stratified for different CYP3A5 genotypes: homozygote 3 3 shown in the left panel* *
and heterozygote 1 3 and homozygote 1 1 shown in the right panel. Red solid line indicates observed data median, red dotted lines are 95* * * * %
observed percentiles, grey shaded area is the simulated median with uncertainty and dark grey shaded areas are simulated 95  percentiles%
with uncertainty.
Figure 5
Schematic view of: left, effect of CYP3A5 genotype on ritonavir - atazanavir first pass effect; right, final linked ritonavir  atazanavir model.–
CYP3A5 3 3 are low expressors and CYP3A5 1 3, 1 1 are high expressors.* * * * * *
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Figure 6
PK profile over 6 months derived based on individual parameter estimates and full dosing histories (grey line) for one patient with VL > 40
cp/mL at week 24. Cumulative time below MEC is shown with a red stair-case line. The target MEC of 150 ng/mL is shown with a dark red
broken line.
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Table 1
Comparison of atazanavir model parameters obtained with three different analyses with respect to dosing histories assumptions. Relative standard errors, expressed in percentages, are given in
parenthesis (except for full MEMS where they were not obtained).
PK Parameters A : SS assumptionss A : Full MEMSMEMS A : Gold standardGOLD 
CL/F (L/h) 7.2 (4.4) 6.8 6.9 (8.1)
V/F (L) 79.2 (8.9) 102 81.1 (6.8)
ka (h )1 − 2.7 (26.8) 5.6 3.2 (42.1)
MTT (h) 1.3 (11.2) 1.5 1.35 (11)
NN 17.3 (46.7) 8 11.5 (26.4)
BSV (CL/F)  * 47.4 (28.7) 44.3 40.2 (32.7)
WSV (CL/F)  * 26.5 (16.9) <1 <1
BSV (V/F)  * 30.0 (43.2) 61.4 30.1 (28.5)
BSV (ka)  * 73.5 (47.2) 120 78.4 (73.2)
BSV (MTT)  * 47.4 (28.7) 40.1 45.2 (31.8)
RV (week 4)  * 18.7 (16.9) 27.7 19.4 (15.5)
RV (> week 4)  * 38.0 (33.1) 47.4 43.4 (10.6)
 * Note: All BSV, WSV and RV are expressed as CV ( ).%
BSV Between-subject variability, WSV Within-subject variability, RV Residual variability, MTT mean transit time, NN number of transit compartments, ka absorption rate constant= = = = = =
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Table 2
Model parameter estimates for the final ritonavir (left column) and joint ritonavir-atazanavir (right column) PK-PG model using a gold standard analysis. Relative standard errors, obtained by
nonparametric bootstrap (n 100) and expressed in percentages, are given in parenthesis.=
Ritonavir Atazanavir
CL/F (L/h) 10.3 (9) 16.0 (64) **
βCYP3A5 1 * - 1.28 (59)
AUC of RTV (ng.h/mL)50 - 6,230 (91)
Emax - 0.98 (3)
V/F (L) 87.9 (11) 81.1 (6)
ka (h )1 − 3.9 (58) 3.3 (146)
MTT (h) 1.1 (16) 1.36 (14)
NN 14.4 (95) 11.5 (29)
BSV (CL/F)  * 38.5 (33) 31 (28)
BSV (V/F)  * 37.3 (50) 31 (33)
Correlation (CL/F-V/F) 0.74 (45) -
BSV (ka)  * 248 (161) 81 (133)
BSV (MTT)  * 49.3 (77) 44 (39)
RV week 4 ( ) %  * 40.8 (8) 19.4 (16)
RV > week 4 ( ) %  * 40.8 (8) 42.3 (10)
 * BSV Between-subject variability, RV Residual variability,= =
 ** (CL/F) atazanavir CL in absence of ritonavir, MTT mean transit time, NN number of transit compartments, ka absorption rate constant, AUC  ritonavir exposure needed for half maximal0 = = = = 50 –
boosting effect, Emax  maximal effect of ritonavir boosting,  factor of increase in atazanavir CL with at least one copy of CYP3A5 1 allele, RV residual variability– βCYP3A5 1 * – * =
